Stay updated with breaking news from Rhonda Hellums. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Positive SLN360 data to be presented in late breaker at the American College of Cardiology (ACC) Annual Meeting on April 3, 2022 SLN124 phase 1 study in thalassemia now fully enrolled; on-track for
Silence Therapeutics, Totus Medicines and Poseida Therapeutics all adjust as they welcome new members to their leadership teams.
Mark Rothera steps down as President and CEO Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), a leader in the discovery, development and delivery of novel short interfering ribonucleic